Factors influencing collection of peripheral blood progenitor cells following high-dose cyclophosphamide and granulocyte colony-stimulating factor in patients with multiple myeloma.
about
Stroma-supported progenitor production as a prognostic tool for graft failure following autologous stem cell transplantation.Hematopoietic stem cell mobilization with intravenous melphalan and G-CSF in patients with chemoresponsive multiple myeloma: report of a phase II trial.Use of bortezomib as induction therapy prior to stem cell transplantation in frontline treatment of multiple myeloma: impact on stem cell harvesting and engraftment.Hematopoietic progenitor cell mobilization using low-dose cyclophosphamide and granulocyte colony-stimulating factor for multiple myeloma.Effect of high-dose plerixafor on CD34+ cell mobilization in healthy stem cell donors: results of a randomized crossover trial.Effect of thalidomide on stem cell collection and engraftment in patients with multiple myeloma.Expression of L-type amino acid transporter 1 (LAT1) as a prognostic and therapeutic indicator in multiple myelomaEffects of induction with novel agents versus conventional chemotherapy on mobilization and autologous stem cell transplant outcomes in multiple myeloma.Evaluation of new automated hematopoietic progenitor cell analysis in the clinical management of peripheral blood stem cell collections.Pegfilgrastim for PBSC mobilization and autologous haematopoietic SCT.Treatment of multiple myeloma: a comprehensive review.Advances in stem cell mobilization.Cyclophosphamide-based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase III trial ReLApsE.Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma.Low-dose or intermediate-dose cyclophosphamide plus granulocyte colony-stimulating factor for progenitor cell mobilisation in patients with multiple myeloma.Dexamethasone, paclitaxel, etoposide, cyclophosphamide (d-TEC) and G-CSF for stem cell mobilisation in multiple myeloma.High-dose melphalan with G-CSF-stimulated whole blood rescue followed by stem cell harvesting and busulphan/cyclophosphamide with autologous stem cell transplantation in multiple myeloma.Effect of prior chemotherapy on hematopoietic stem cell mobilization.Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy-era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF.ESHAP plus G-CSF as an effective peripheral blood progenitor cell mobilization regimen in pretreated non-Hodgkin's lymphoma: comparison with high-dose cyclophosphamide plus G-CSF.A randomized trial of etoposide and G-CSF with or without rituximab for PBSC mobilization in B-cell non-Hodgkin's lymphoma.Peripheral blood hematopoietic stem cell mobilization and collection efficacy is not an independent prognostic factor for autologous stem cell transplantation.First-line thalidomide-dexamethasone therapy in preparation for autologous stem cell transplantation in young patients (<61 years) with symptomatic multiple myeloma.Analysis of remobilization success in patients undergoing autologous stem cell transplants who fail an initial mobilization: risk factors, cytokine use and cost.Optimal mobilization method and CD34+ dose calculation for autologous PBSC transplant in myeloma patients: two important unresolved questions.Growth factor plus preemptive ('just-in-time') plerixafor successfully mobilizes hematopoietic stem cells in multiple myeloma patients despite prior lenalidomide exposure.Mathematical model of peripheral blood stem cell harvest kinetics.Stem cell mobilization and autologous stem cell transplantation after pretreatment with bendamustine, prednisone and bortezomib (BPV) in newly diagnosed multiple myeloma.Mobilization of peripheral blood progenitor cells after DHAP regimen with or without rituximab: a large multicenter comparative study in patients with malignant lymphoma.
P2860
Q33335451-457758C7-726C-40EC-88CB-1CBD0A18B905Q33364465-AC37357C-085D-4D1B-8704-1D7EFF2794BCQ33376918-34D141BC-1F1B-4FBE-901F-538867A54E72Q33408698-2D4A4434-0B98-4C19-9ECE-429F2F0CAF37Q33573756-D87AAD33-0DAA-4044-8348-9DE297AE6CE0Q35210732-6A59C0E4-45F0-47D2-946E-42D742E3623EQ35713446-DF312C56-93AC-44BC-9377-63DFDA8FF427Q36570256-E7C33FA4-63E4-4E1F-8741-D481ACA1FC38Q37158660-A5BCACD1-CB7E-408E-9A32-463134C15C36Q37421288-BA8A7304-1407-4C9A-A730-DEB5CF86E0D3Q37542173-7D97E945-021F-48A8-98F9-A833AA1CDCA9Q38183225-492C546A-FFA4-45D1-8822-66EB93D4DF44Q38859426-DD23F7AE-4D57-4D3E-AA06-C60DDA222539Q40201943-C70F62C1-F795-4A94-9D8C-E630A2F15730Q40563622-99B5397D-C8F8-4C52-B932-FF177538F4E7Q40597777-C118AD27-77E0-4097-9268-8D905A3F501AQ43661033-0A65D87D-3852-4953-A103-C4FEFB553235Q44788991-07A1467B-3DD7-4F14-B244-3A39E7581FACQ44986060-5D1985CD-C2CC-4684-8F14-FD68A9462CA6Q45227050-A95D7DA6-2465-4AA1-BD96-C41C3F78BCE9Q46365024-4C81D13C-88B0-4567-A343-4B9FEAE32B5DQ46469277-A6A39937-35B9-4185-9E30-CC544D58C0B4Q46558044-C951AE05-2FF9-4D8D-B70B-5192D5938896Q47818018-756C92F9-400F-40CC-8429-32E3ACDCB2C6Q47966106-3FA6FEAA-0A86-48F4-8823-EF9DDE7B15FEQ51385709-C6E0718D-8B34-4D2F-9E5D-735BDE00AE52Q52008594-7F20041C-1765-4C15-8DA3-E9EB7BAB454CQ53504691-2BE8D937-72C7-4EA4-8ED0-FE38A5EC0BB0Q53571230-D55FB7A6-2568-4FEC-B205-C94AD66B8A98
P2860
Factors influencing collection of peripheral blood progenitor cells following high-dose cyclophosphamide and granulocyte colony-stimulating factor in patients with multiple myeloma.
description
1997 nî lūn-bûn
@nan
1997 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
Factors influencing collection ...... atients with multiple myeloma.
@ast
Factors influencing collection ...... atients with multiple myeloma.
@en
type
label
Factors influencing collection ...... atients with multiple myeloma.
@ast
Factors influencing collection ...... atients with multiple myeloma.
@en
prefLabel
Factors influencing collection ...... atients with multiple myeloma.
@ast
Factors influencing collection ...... atients with multiple myeloma.
@en
P2093
P1476
Factors influencing collection ...... atients with multiple myeloma.
@en
P2093
Goldschmidt H
Hegenbart U
Wallmeier M
P304
P356
10.1046/J.1365-2141.1997.2783095.X
P407
P577
1997-09-01T00:00:00Z